vs

Side-by-side financial comparison of Lipocine Inc. (LPCN) and Versus Systems Inc. (VS). Click either name above to swap in a different company.

Versus Systems Inc. is the larger business by last-quarter revenue ($2.2M vs $1.1M, roughly 1.9× Lipocine Inc.).

Lipocine Inc is a clinical-stage biopharmaceutical company specializing in the development of hormone-based therapies. Its core product pipeline targets unmet medical needs in men's health, women's health, and liver disease, with primary operations and market focus in the United States. It prioritizes oral formulation innovation to improve patient treatment accessibility and adherence.

Versus Systems Inc. operates a proprietary interactive reward platform that integrates with video games, streaming content, live sports broadcasts and mobile apps. It enables content creators and brands to offer personalized real-time prizes to audiences across North America and global digital entertainment markets.

LPCN vs VS — Head-to-Head

Bigger by revenue
VS
VS
1.9× larger
VS
$2.2M
$1.1M
LPCN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LPCN
LPCN
VS
VS
Revenue
$1.1M
$2.2M
Net Profit
$-964.9K
Gross Margin
0.2%
Operating Margin
-54.2%
Net Margin
-44.7%
Revenue YoY
-67.2%
Net Profit YoY
-233.0%
-19.2%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LPCN
LPCN
VS
VS
Q4 25
$1.1M
$2.2M
Q3 25
$0
Q2 25
$-176.0K
Q4 24
$0
Q3 24
$0
Q1 24
$7.6M
Q2 23
$157.9K
Q3 22
$316.8K
Net Profit
LPCN
LPCN
VS
VS
Q4 25
$-964.9K
Q3 25
$-537.8K
Q2 25
$672.3K
Q4 24
$-809.5K
Q3 24
$-2.2M
Q1 24
$3.5M
Q2 23
$-2.3M
Q3 22
$-3.5M
Gross Margin
LPCN
LPCN
VS
VS
Q4 25
0.2%
Q3 25
Q2 25
Q4 24
Q3 24
Q1 24
Q2 23
79.5%
Q3 22
Operating Margin
LPCN
LPCN
VS
VS
Q4 25
-54.2%
Q3 25
Q2 25
Q4 24
Q3 24
Q1 24
42.3%
Q2 23
-840.1%
Q3 22
Net Margin
LPCN
LPCN
VS
VS
Q4 25
-44.7%
Q3 25
Q2 25
-382.0%
Q4 24
Q3 24
Q1 24
46.1%
Q2 23
-1462.9%
Q3 22
-1107.9%
EPS (diluted)
LPCN
LPCN
VS
VS
Q4 25
Q3 25
Q2 25
$0.14
Q4 24
$-0.27
Q3 24
$-0.44
Q1 24
$0.66
Q2 23
$-2.41
Q3 22
$-1.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LPCN
LPCN
VS
VS
Cash + ST InvestmentsLiquidity on hand
$5.2M
$527.4K
Total DebtLower is stronger
Stockholders' EquityBook value
$14.5M
$10.2M
Total Assets
$17.0M
$2.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LPCN
LPCN
VS
VS
Q4 25
$5.2M
$527.4K
Q3 25
Q2 25
Q4 24
$3.1M
Q3 24
$3.7M
Q1 24
$3.1M
Q2 23
$3.2M
Q3 22
$1.0M
Stockholders' Equity
LPCN
LPCN
VS
VS
Q4 25
$14.5M
$10.2M
Q3 25
$11.1M
Q2 25
$11.7M
Q4 24
$11.4M
Q3 24
$19.1M
Q1 24
$24.0M
Q2 23
$6.4M
Q3 22
$14.1M
Total Assets
LPCN
LPCN
VS
VS
Q4 25
$17.0M
$2.1M
Q3 25
$3.1M
Q2 25
$3.8M
Q4 24
$3.5M
Q3 24
$20.7M
Q1 24
$25.4M
Q2 23
$9.5M
Q3 22
$17.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LPCN
LPCN
VS
VS
Operating Cash FlowLast quarter
$-9.8M
$-568.6K
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LPCN
LPCN
VS
VS
Q4 25
$-9.8M
$-568.6K
Q3 25
$24.7K
Q2 25
$-867.5K
Q4 24
$-716.6K
Q3 24
$-2.8M
Q1 24
$2.4M
Q2 23
$-1.3M
Q3 22
$-1.7M
Cash Conversion
LPCN
LPCN
VS
VS
Q4 25
Q3 25
Q2 25
-1.29×
Q4 24
Q3 24
Q1 24
0.69×
Q2 23
Q3 22

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons